Eligible subjects may enroll into this open label study upon completing their final study visit of Study AXS-05-AD-302 or AXS-05-AD-304.
This is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with agitation associated with Alzheimer's disease (AD).